Collectively, these findings redefine SLAMF7 as both an immune cell activator and a dual-function antigen in myeloma pathobiology, with its membrane and soluble forms exerting opposing effects that are therapeutically targetable by elotuzumab. Here, SLAMF7 is linked to plasma cell myeloma.